WST Maintains Buy Rating -- Price Target Raised to $420 by TD Cowen

gurufocus.com · 2026-10-13

On October 13, 2026, TD Cowen maintained a Buy rating on West Pharmaceutical Services (WST), raising the price target from $410.00 to $420.00. This adjustment r

TickrTrends take: WST's maintenance of a buy rating with an elevated price target from TD Cowen provides context for evaluating whether the Fairly valued assessment aligns with analyst expectations in the Healthcare sector. A valuation-focused reader should monitor whether this analyst action reflects confidence in fundamental performance or represents a gap between current market pricing and the higher target, which could signal either near-term upside potential or a divergence from intrinsic value estimates. The persistence of buy-side sentiment at a raised target suggests analysts see catalysts ahead, though this should be weighed against TickrTrends' current valuation stance.

Read the full story at gurufocus.com →